Literature DB >> 11850694

Low-Dose Aspirin and Ibuprofen Reduce the Cutaneous Reactions Following Niacin Administration.

Raymond T. Dunn1, Marjorie A. Ford, Joseph P. Rindone, Fabia A. Kwiecinski.   

Abstract

BACKGROUND: Moderate doses of prostaglandin inhibitors may reduce the cutaneous reactions from niacin administration. We undertook this study to determine if low doses of either ibuprofen or aspirin reduces cutaneous reactions from niacin in healthy volunteers.
METHODS: Twenty-two subjects were randomized to received crystalline niacine 500 mg preceded by either placebo, aspirin 165 mg, aspirin 325 mg, or ibuprofen 200 mg. The study was crossover and double blinded, and treatment arms were separated by 2 days. Subjects were asked to rate the severity of flushing, itching, and tingling after niacin on a visual analog scale (0---no symptoms; 10---severe symptoms). Statistical analysis was performed using repeated measures of analysis of variance.
RESULTS: Nineteen of the 22 subjects completed the protocol. Overall, aspirin 325 mg statistically reduced flushing after niacin administration. No statistical difference was observed for the other treatment arms for either flushing, itching, or tingling. When subjects experiencing the worse symptoms were analyzed separately, all treatment arms statistically reduced the flushing, itching, or tingling from niacin. Aspirin 325 mg was the most efficacious, followed by aspirin 165 mg and ibuprofen 200 mg.
CONCLUSION: These data demonstrate that pretreatment with low doses of aspirin or ibuprofen are effective in reducing cutaneous reactions from niacin administration.

Entities:  

Year:  1995        PMID: 11850694     DOI: 10.1097/00045391-199506000-00006

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  11 in total

Review 1.  A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2010-04       Impact factor: 7.616

Review 2.  Niacin: another look at an underutilized lipid-lowering medication.

Authors:  Julia C Creider; Robert A Hegele; Tisha R Joy
Journal:  Nat Rev Endocrinol       Date:  2012-02-21       Impact factor: 43.330

3.  Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany.

Authors:  Galin V Michailov; Glenn M Davies; Karl J Krobot
Journal:  Eur J Health Econ       Date:  2011-04-05

4.  Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

Authors:  Kang Cheng; Tsuei-Ju Wu; Kenneth K Wu; Claudio Sturino; Kathleen Metters; Keith Gottesdiener; Samuel D Wright; Zhaoyin Wang; Gary O'Neill; Eseng Lai; M Gerard Waters
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

Review 5.  Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.

Authors:  Klaus G Parhofer
Journal:  Vasc Health Risk Manag       Date:  2009-11-16

6.  The flavonoid luteolin inhibits niacin-induced flush.

Authors:  D Papaliodis; W Boucher; D Kempuraj; T C Theoharides
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

7.  Attenuation of niacin-induced prostaglandin D(2) generation by omega-3 fatty acids in THP-1 macrophages and Langerhans dendritic cells.

Authors:  Justin Vanhorn; Jeffrey D Altenburg; Kevin A Harvey; Zhidong Xu; Richard J Kovacs; Rafat A Siddiqui
Journal:  J Inflamm Res       Date:  2012-03-14

Review 8.  The mechanism and mitigation of niacin-induced flushing.

Authors:  V S Kamanna; S H Ganji; M L Kashyap
Journal:  Int J Clin Pract       Date:  2009-09       Impact factor: 2.503

Review 9.  Mechanisms of flushing due to niacin and abolition of these effects.

Authors:  Aditya Sood; Rohit Arora
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-11       Impact factor: 3.738

Review 10.  Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.

Authors:  Jennifer G Robinson
Journal:  Vasc Health Risk Manag       Date:  2009-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.